secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0001171843-24-001035
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cassava Sciences reports FY2023 net loss of $97.2M; Phase 3 topline data expected year-end 2024
--------------------------------------------------------------------------------

- Net loss $97.2M ($2.32/share) vs $76.2M ($1.90) in 2022; R&D expenses $89.4M.
- Cash and equivalents $121.1M at 12/31/23; $21.8M raised in 2024 from warrant exercises.
- Over 555 patients completed Phase 3 studies; topline data for 52-week trial expected year-end 2024.
- Internal investigation found no evidence substantiating allegations of research misconduct.
- Net cash used in operations $82M in 2023; expected $35-45M in H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000117184324001035/0001171843-24-001035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000117184324001035/f8k_022824.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-001035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer